Latest Advances in Lung Cancer Research

The phase 3 Pragmatica-Lung study has broader eligibility criteria than many other trials, expanding access to more patients and clinicians.

New clinical trial shows improved survival rates and reduced risk of recurrence in patients taking a targeted therapy for NSCLC.

Lung cancer screening may accelerate the shift of the lung cancer stage from an advanced incurable stage toward an early curable disease, which may improve survival.

A new phase I/II clinical trial shows that repotrectinib had anti tumor activity in participants with the ROS-1-gene.

GSK’s TIM-3 lung cancer drug is moving into a pivotal trial after hitting the mark in the midphase portion of the study.

After results from a phase 2 trial, the FDA granted fast track designation to sapanisertib for patients with certain non–small cell lung cancer.

In SAVANNAH Phase II trial, Tagrisso + savolitinib showed a 49% objective response rate in lung cancer patients with certain MET biomarkers.

Sotorasib drug shows meaningful benefits clincally with advanced KRAS G12C mutation in non-small cell lung cancer patients.